



GENOMENON

For Immediate Release

October 28, 2016

Genomenon CEO Mike Klein Appears on Michigan Business Rap's Entrepreneurial Friday Radio Show

Ann Arbor, Mich. - October 28, 2016 - Genomenon's CEO Mike Klein was featured as a guest panelist on the Entrepreneurial Friday radio show hosted by Michigan Business Rap. Klein was joined by hosts Tony Cuthbert, as well as fellow panelists including Rich Chylla, the Executive Director of MSU Technologies, Denise Graves, the University Relations Director at the MEDC and Alain Piette, the Technology Team Manager of Michigan Small Business Development Centers.

The panel was brought together to discuss how many area business and startups begin in the area universities across Michigan. The experts discussed the collaboration between Michigan state resources, universities and business founders, as well as the process from ideation to maturation, examining the process of a start-up from university development through success as a business.

Klein was able to offer insight to how mentors and successful entrepreneurs can support Michigan universities and help foster entrepreneurial activities in the area. Klein was able to further discuss how several area grants and competitions were able to help grow the Genomenon concept and build the steps to create a product that is helping scientists and clinicians solve cancer with DNA software. He also touched on topics including garnering capital, raising funds for development and his experience as a Fellow Mentor in Residence at the University of Michigan.

To hear the program in it's entirety, please visit <http://bit.ly/2eKIUFP>

About Genomenon:

Genomenon's genome interpretation software is used for clinical diagnostics in cancer and genetic diseases. Genomenon reduces the time Pathologists and Geneticists spend researching and interpreting genetic variants from hours to minutes. Mastermind, our comprehensive knowledge-base, is built on mining millions of medical publications that automatically finds correlations between genes, variants and diseases tied to the primary scientific literature required for clinical diagnosis.

For more information, visit www.genomenon.com or email sales@genomenon.com.

Press Contact: Jessica Francis 440.840.4987 or email jessicafrancisPR@gmail.com